CN113473983B - 通过施用树脂毒素治疗帕金森病的方法 - Google Patents

通过施用树脂毒素治疗帕金森病的方法 Download PDF

Info

Publication number
CN113473983B
CN113473983B CN201980092939.6A CN201980092939A CN113473983B CN 113473983 B CN113473983 B CN 113473983B CN 201980092939 A CN201980092939 A CN 201980092939A CN 113473983 B CN113473983 B CN 113473983B
Authority
CN
China
Prior art keywords
aav
rtx
mice
null
gait
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980092939.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113473983A (zh
Inventor
亚历西斯·拿哈马
H·H·吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorento Pharmaceutical Co ltd
Original Assignee
Sorento Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorento Pharmaceutical Co ltd filed Critical Sorento Pharmaceutical Co ltd
Publication of CN113473983A publication Critical patent/CN113473983A/zh
Application granted granted Critical
Publication of CN113473983B publication Critical patent/CN113473983B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980092939.6A 2018-12-24 2019-12-23 通过施用树脂毒素治疗帕金森病的方法 Active CN113473983B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862784650P 2018-12-24 2018-12-24
US62/784,650 2018-12-24
US201962914170P 2019-10-11 2019-10-11
US62/914,170 2019-10-11
PCT/US2019/068235 WO2020139797A1 (en) 2018-12-24 2019-12-23 Methods for treating parkinson's disease by administering resiniferatoxin

Publications (2)

Publication Number Publication Date
CN113473983A CN113473983A (zh) 2021-10-01
CN113473983B true CN113473983B (zh) 2024-07-23

Family

ID=71126251

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092939.6A Active CN113473983B (zh) 2018-12-24 2019-12-23 通过施用树脂毒素治疗帕金森病的方法

Country Status (8)

Country Link
US (1) US12201608B2 (https=)
EP (1) EP3902539B1 (https=)
JP (1) JP7519359B2 (https=)
KR (1) KR20210107086A (https=)
CN (1) CN113473983B (https=)
AU (1) AU2019414329A1 (https=)
CA (1) CA3124499A1 (https=)
WO (1) WO2020139797A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108979A (ko) 2018-12-21 2021-09-03 소렌토 쎄라퓨틱스, 인코포레이티드 부적응 통증을 치료하기 위한 레시니페라톡신의 신경 주위 투여
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
JP7530365B2 (ja) 2019-01-22 2024-08-07 ソレント・セラピューティクス・インコーポレイテッド レシニフェラトキシンを投与することによって変形性関節症疼痛を処置するための方法
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
MXPA05006670A (es) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
WO2008109026A1 (en) 2007-03-05 2008-09-12 Mt Cook Pharma Pharmaceutical compositions for the localized treatment of neurogenic dysfunction
DK2222289T3 (da) * 2007-11-19 2013-10-07 Nestec Sa Behandling af oral pharyngeal dysphagi
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN105017155B (zh) * 2014-04-16 2017-06-16 华东师范大学 类三环二萜并吡唑衍生物及其制备方法和应用
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
CN107126445A (zh) * 2017-04-20 2017-09-05 江南大学 粪菌移植在治疗帕金森病方面的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dorothy Cimino Brown.Resiniferatoxin: The Evolution of the "Molecular Scalpel" for Chronic Pain Relief.Pharmaceuticals.2016,1-11. *
Resiniferatoxin: The Evolution of the "Molecular Scalpel" for Chronic Pain Relief;Dorothy Cimino Brown;Pharmaceuticals;1-11 *
TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson’s disease via CNTF;Jin H. Nam等;BRAIN;3610-3622 *

Also Published As

Publication number Publication date
JP2022514695A (ja) 2022-02-14
US20210299090A1 (en) 2021-09-30
CA3124499A1 (en) 2020-07-02
EP3902539B1 (en) 2024-07-31
CN113473983A (zh) 2021-10-01
EP3902539A4 (en) 2022-08-24
WO2020139797A1 (en) 2020-07-02
KR20210107086A (ko) 2021-08-31
EP3902539A1 (en) 2021-11-03
JP7519359B2 (ja) 2024-07-19
AU2019414329A1 (en) 2021-06-10
US12201608B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
CN113473983B (zh) 通过施用树脂毒素治疗帕金森病的方法
CA2761156C (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
Niu et al. Effect of bilateral deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease
Luciano et al. Role of catheter's position for final results in intrathecal drug delivery. Analysis based on CSF dynamics and specific drugs profiles
Haridas et al. Pallidal deep brain stimulation for primary dystonia in children
Ying et al. Motor and somatosensory evoked potentials in coma: analysis and relation to clinical status and outcome.
US20040209810A1 (en) Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
Sobstyl et al. Long-term clinical outcome of bilateral pallidal stimulation for intractable craniocervical dystonia (Meige syndrome). Report of 6 patients
Puniak et al. Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma
Krilis et al. Vision loss and partial third nerve palsy following contralateral peribulbar anesthesia
Duffey et al. Progressive deterioration of intellect and motor function occurring several decades after cranial irradiation: a new facet in the clinical spectrum of radiation encephalopathy
Hosseini et al. Unilateral thalamic deep brain stimulation for disabling kinetic tremor in multiple sclerosis
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
Li et al. Effects of l-dopa methyl ester on visual cortex injury induced by amblyopia and its underlying mechanism
US20240252582A1 (en) Methods for treating amblyopia
US8633165B2 (en) Neuroprotective effects of 2DG in traumatic brain injury
DiMario Jr Tuberous sclerosis complex
Guidine et al. Electroencephalographic evidence of brainstem recruitment during scorpion envenomation
Lawless Minocycline plus N-acetylcysteine improve chronic and progressive structural and functional deficits following a single TBI in male mice
KR20240090983A (ko) 신경 복원 촉진에 사용되는 이소로이폴린 및 그 유도체의 용도
Mezer et al. Measuring recovery of visual function in children with papilledema using sweep visual evoked potentials
CN114617865A (zh) 乙酰左旋肉碱在制备用于预防或治疗静脉流出障碍性疾病的药物中的应用
Halim Parkinson disease therapy during Ramadhan fasting month. A case report
Nose et al. A potential therapeutic option for postural deformities in Parkinson disease
Potchinkova APITHERAPY BY ACUPUNCTURE IN NEUROLOGICAL COMPLICATIONS OF SPONDYLARTHRITIS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant